0 9 Antisense antisense JJ 10 26 oligonucleotides oligonucleotide NNS 27 29 to to TO 30 33 the the DT 34 37 p65 p65 NN 38 45 subunit subunit NN 46 48 of of IN 49 57 NF-kappa NF-kappa NNP 58 59 B B NNP 60 65 block block VBP 66 71 CD11b CD11b NNP 72 82 expression expression NN 83 86 and and CC 87 92 alter alter VB 93 101 adhesion adhesion NN 102 112 properties property NNS 113 115 of of IN 116 130 differentiated differentiate VBN 131 136 HL-60 hl-60 NN 137 149 granulocytes granulocyte NNS 149 150 . . . 152 160 NF-kappa NF-kappa NNP 161 162 B B NNP 163 165 is be VBZ 166 167 a a DT 168 179 pleiotropic pleiotropic JJ 180 189 regulator regulator NN 190 192 of of IN 193 194 a a DT 195 202 variety variety NN 203 205 of of IN 206 211 genes gene NNS 212 222 implicated implicate VBN 223 225 in in IN 226 229 the the DT 230 238 cellular cellular JJ 239 247 response response NN 248 250 to to TO 251 257 injury injury NN 257 258 . . . 259 263 This this DT 264 272 function function NN 273 276 has have VBZ 277 281 been be VBN 282 292 attributed attribute VBN 293 295 to to TO 296 299 the the DT 300 311 coordinated coordinate VBN 312 319 binding binding NN 320 322 of of IN 323 331 subunits subunit NNS 332 334 of of IN 335 343 NF-kappa NF-kappa NNP 344 345 B B NNP 346 348 to to TO 349 357 distinct distinct JJ 358 365 regions region NNS 366 368 of of IN 369 372 the the DT 373 381 promoter promoter NN 382 390 elements element NNS 391 393 of of IN 394 402 numerous numerous JJ 403 408 genes gene NNS 408 409 , , , 410 419 including include VBG 420 429 cytokines cytokine NNS 429 430 , , , 431 437 growth growth NN 438 444 factor factor NN 445 454 receptors receptor NNS 454 455 , , , 456 459 and and CC 460 468 adhesion adhesion NN 469 478 molecules molecule NNS 478 479 . . . 480 489 Antisense antisense JJ 490 506 phosphorothioate phosphorothioate NN 507 523 oligonucleotides oligonucleotide NNS 524 526 to to TO 527 530 the the DT 531 534 p50 p50 NN 535 538 and and CC 539 542 p65 p65 NN 543 551 subunits subunit NNS 552 554 of of IN 555 558 the the DT 559 567 NF-kappa NF-kappa NNP 568 569 B B NNP 570 577 complex complex NN 578 582 were be VBD 583 587 used use VBN 588 590 to to TO 591 597 define define VB 598 601 the the DT 602 613 physiologic physiologic JJ 614 618 role role NN 619 621 of of IN 622 626 this this DT 627 640 transcription transcription NN 641 647 factor factor NN 648 650 in in IN 651 658 resting rest VBG 659 662 and and CC 663 673 stimulated stimulate VBN 674 686 granulocytes granulocyte NNS 686 687 . . . 688 689 A a DT 690 699 reduction reduction NN 700 702 in in IN 703 706 the the DT 707 717 expression expression NN 718 720 of of IN 721 724 p65 p65 NN 725 728 was be VBD 729 737 produced produce VBN 738 740 by by IN 741 750 treatment treatment NN 751 755 with with IN 756 759 the the DT 760 776 phosphorothioate phosphorothioate NN 777 786 antisense antisense JJ 787 807 oligodeoxynucleotide oligodeoxynucleotide NN 807 808 . . . 809 813 This this DT 814 823 reduction reduction NN 824 827 was be VBD 828 839 accompanied accompany VBN 840 842 by by IN 843 848 rapid rapid JJ 849 856 changes change NNS 857 859 in in IN 860 863 the the DT 864 872 cellular cellular JJ 873 881 adhesion adhesion NN 882 884 of of IN 885 893 dimethyl dimethyl NN 894 918 sulfoxide-differentiated sulfoxide-differentiated JJ 919 924 HL-60 hl-60 NN 925 933 leukemia leukemia NN 934 939 cells cell NNS 940 950 stimulated stimulate VBN 951 953 by by IN 954 979 12-O-tetradecanoylphorbol 12-O-tetradecanoylphorbol NNP 980 990 13-acetate 13-acetate NN 991 992 ( ( ( 992 995 TPA TPA NNP 995 996 ) ) ) 996 997 . . . 998 1003 These these DT 1004 1011 effects effect NNS 1012 1016 were be VBD 1017 1030 characterized characterize VBN 1031 1033 by by IN 1034 1035 a a DT 1036 1042 marked marked JJ 1043 1052 reduction reduction NN 1053 1055 in in IN 1056 1061 CD11b CD11b NNP 1062 1070 integrin integrin NN 1071 1081 expression expression NN 1082 1084 on on IN 1085 1088 the the DT 1089 1096 surface surface NN 1097 1099 of of IN 1100 1107 treated treat VBN 1108 1113 cells cell NNS 1113 1114 . . . 1115 1126 Furthermore furthermore RB 1126 1127 , , , 1128 1131 the the DT 1132 1135 p65 p65 NN 1136 1145 antisense antisense JJ 1146 1154 oligomer oligomer NN 1155 1166 effectively effectively RB 1167 1176 abolished abolish VBD 1177 1179 an an DT 1180 1192 upregulation upregulation NN 1193 1195 of of IN 1196 1201 CD11b CD11b NNP 1202 1206 that that WDT 1207 1210 was be VBD 1211 1219 produced produce VBN 1220 1222 by by IN 1223 1241 formyl-met-leu-phe formyl-met-leu-phe NN 1242 1245 and and CC 1246 1249 TPA TPA NNP 1249 1250 . . . 1251 1258 However however RB 1258 1259 , , , 1260 1263 the the DT 1264 1267 p65 p65 NN 1268 1277 antisense antisense JJ 1278 1294 phosphorothioate phosphorothioate NN 1295 1315 oligodeoxynucleotide oligodeoxynucleotide NN 1316 1319 had have VBD 1320 1322 no no DT 1323 1334 significant significant JJ 1335 1341 effect effect NN 1342 1344 on on IN 1345 1348 the the DT 1349 1359 production production NN 1360 1362 of of IN 1363 1371 reactive reactive JJ 1372 1378 oxygen oxygen NN 1379 1392 intermediates intermediate NNS 1393 1395 or or CC 1396 1398 on on IN 1399 1411 phagocytosis phagocytosis NN 1412 1414 by by IN 1415 1420 these these DT 1421 1426 cells cell NNS 1426 1427 . . . 1428 1433 These these DT 1434 1442 findings finding NNS 1443 1451 indicate indicate VBP 1452 1456 that that IN 1457 1466 antisense antisense JJ 1467 1476 oligomers oligomer NNS 1477 1479 to to TO 1480 1483 p65 p65 NN 1484 1487 can can MD 1488 1490 be be VB 1491 1495 used use VBN 1496 1498 to to TO 1499 1505 define define VB 1506 1509 the the DT 1510 1514 role role NN 1515 1517 of of IN 1518 1526 NF-kappa NF-kappa NNP 1527 1528 B B NNP 1529 1531 in in IN 1532 1535 the the DT 1536 1546 activation activation NN 1547 1555 pathways pathway NNS 1556 1558 of of IN 1559 1570 neutrophils neutrophil NNS 1570 1571 . . .